Mark Chapman
Long only, contrarian, event-driven

Could Teva & Pfizer End Up In A Bidding War For Antares?

On January 15, I found it very interesting that the CFO of Teva Pharmaceuticals (NASDAQ:TEVA) indicated that Teva had plans to return to a deal making strategy on the same day that Antares Pharma (NASDAQ:ATRS) announced the launch of OTREXUP. OTREXUP has a chance to be a transformational product for Antares, since it takes a well established rheumatoid arthritis drug in methotrexate, and changes the delivery method from an oral pill to a self administered subcutaneous injection. Subcutaneous injection not only allows for greater blood levels of medication than oral, but may also cut down on the gastrointestinal side effects from the oral medication. Given that Antares has taken the current standard of care drug...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details